Peptide API CRDMO & Injectable Facility Validation
WinHyCare supplies Semaglutide API and partners with pharmaceutical companies as a peptide CRDMO and injectable-facility validation specialist — process development, analytical, regulatory and qualification services that de-risk your path to compliant, market-ready product.
WinHyCare brings two capabilities under one audit-ready quality system: a peptide CRDMO partnership — taking programmes from sequence and process optimisation, through analytical and regulatory documentation, with Semaglutide API supplied as our catalog product — and end-to-end qualification & validation for injectable formulation facilities.
Two Capability Pillars, One Accountable Partner
01Peptide SciencePeptide API CRDMO
Semaglutide API supply plus contract research & development — process, analytical and regulatory services for complex peptides.
- ✓Semaglutide API supply
- ✓≥99% QC methods
- ✓US-DMF / CTD support
- ✓Tech transfer
02Sterile OperationsInjectable Facility Qualification & Validation
End-to-end qualification and validation services for injectable formulation facilities — GMP compliance, built in.
- ✓IQ / OQ / PQ execution
- ✓Facility & utility validation
- ✓Aseptic & sterilization
- ✓CSV & 21 CFR Part 11
Peptide API CRDMO
Semaglutide API supply, plus development, analytical and regulatory services that take complex peptide programmes from sequence to a documented, tech-transfer-ready process.
Integrated B2B Service Suite
Semaglutide API Supply
The peptide API WinHyCare supplies — high-purity Semaglutide, shipped with a Certificate of Analysis under validated cold-chain.
Process Development
Sequence and route optimisation, coupling/cleavage strategy and purification development for complex peptides — tech-transfer-ready.
Analytical Development
UPLC/HPLC and LC-MS method development, impurity profiling and ICH Q2(R1) method-validation packages.
Regulatory Dossiers
US-DMF Type II support, CEP files and CTD Module 3 CMC documentation, prepared to reference for IND / NDA / ANDA.
Quality & Audit Readiness
QA assessment, facility mock audits and pre-approval-inspection (PAI) readiness aligned with FDA, EMA and PMDA expectations.
Technology Transfer
Documented tech-transfer protocols and validation-batch design to move a developed process to your site.
Technical B2B Support
A dedicated desk to resolve regulator deficiency letters, information requests and customer QA queries in real time.
Chemistry & Process Expertise
Our peptide development expertise applies advanced methodologies to suppress side reactions, preserve stereochemical purity and isolate the target API, then make the process reproducible and transferable.
Solid-Phase Peptide Synthesis (SPPS)
Optimised Fmoc protocols and automated synthesiser methods that suppress racemisation, deletions and truncations for high crude purity.
Long-Chain & Modified Peptides
Lipidation and conjugation chemistry for complex, acylated sequences beyond 40 amino acids.
High-Resolution Purification
Preparative dynamic axial compression (DAC) HPLC method development for sharp isolation of the target peptide from close impurities.
Process to kg scale
development & tech transfer
Preparative DAC HPLC
sharp purification methods
Lyophilisation cycles
stable API powder
ICH Q-series aligned
audit-ready records
Zero-Defect Quality Control
Target release purity of ≥99.0%, with individual impurities held strictly below 0.10%, fully characterised and documented. Supplied Semaglutide API ships with a Certificate of Analysis.
UPLC / HPLC Analysis
High-resolution liquid chromatography to determine exact purity.
LC-MS Impurity Profiling
Mass spectrometry to confirm sequence and monitor minor structural variants.
Full Traceability
Documentation from raw materials and resins to final batch-release records.
ICH Stability Testing
Long-term and accelerated study design under ICH Q1A(R2) guidelines.
Regulatory & Documentation Support
We compile comprehensive data packages that enable client submissions and streamline global regulatory review, saving valuable time during filings.
- ✓US-DMF Type II dossier support with process and material-validation data
- ✓CTD Module 3 CMC documentation, prepared to reference for IND / NDA / ANDA
- ✓Analytical method-validation packages compliant with ICH Q2(R1)
- ✓Real-time and accelerated stability study design with secure SOP access
GLP-1 Analog — Route Optimisation
1. The Challenge
A partner's route for a 31-amino-acid lipidated GLP-1 produced significant deletion sequences and diastereomers, holding yield below 25%.
2. The Solution
We re-engineered the SPPS route with optimised resin loading and an Oxyma/DIC coupling system, then developed a dynamic-pH preparative HPLC purification.
3. The Outcome
A kilogram-capable process reaching >99.0% purity with no single impurity above 0.10% and a 120% yield improvement — documented and tech-transfer-ready.
Therapeutic Peptide Classes — Reference
Molecules within the scope of our development, analytical and regulatory experience. Semaglutide API is the product WinHyCare supplies; the remaining molecules are listed for reference and are not offered for supply.
| Compound | CAS | Indication | Focus area | Status |
|---|---|---|---|---|
| Semaglutide | 910463-68-2 | Obesity / Diabetes | GLP-1 Agonist | ● Supplied |
| Tirzepatide | 2023788-19-2 | Obesity / Diabetes | GLP-1 Agonist | Reference |
| Retatrutide | 2381089-83-2 | Obesity / Diabetes | GLP-1 Agonist | Reference |
| Cagrilintide | 1415456-99-3 | Weight management | Amylin analogue | Reference |
| Survodutide | 2805997-46-8 | Obesity / MASH | GLP-1 Agonist | Reference |
| Mazdutide | 2259884-03-0 | Obesity / Diabetes | GLP-1 Agonist | Reference |
| Amycretin | 3005889-81-3 | Obesity / Diabetes | GLP-1 Agonist | Reference |
| Sermorelin | 86168-78-7 | Growth deficiency | Growth / Metabolism | Reference |
| Tesamorelin | 218949-48-5 | Lipodystrophy | Growth / Metabolism | Reference |
| CJC-1295 | 863288-34-0 | Growth hormone | Growth / Metabolism | Reference |
| AOD-9604 | 221231-10-3 | Obesity / Lipolysis | Growth / Metabolism | Reference |
| TB-500 (Thymosin β-4) | 77591-33-4 | Tissue repair | Regenerative | Reference |
| BPC-157 | 137525-51-0 | Inflammatory bowel | Regenerative | Reference |
| Teduglutide | 197922-42-2 | Short-bowel syndrome | Gastrointestinal | Reference |
| Linaclotide | 851199-59-2 | IBS-C / Constipation | Gastrointestinal | Reference |
| Eloralintide | 2838634-40-8 | Weight management | Amylin analogue | Reference |
For B2B pharmaceutical development and research use. WinHyCare does not sell APIs to individuals or for direct human consumption. Regulatory status varies by molecule and market.
Securing Your Supply Chain
Supplied Semaglutide API moves through validated cold-chain logistics that protect shipments and maintain material integrity across international borders.
- 01
Active temperature monitoring
Validated thermal packaging with continuous data logging.
- 02
Multi-region customs record
Clearance & documentation for the US, Europe and Asia.
- 03
Scalable delivery planning
Standing supply orders and safety-stock reserves.
Injectable Formulation Facility — Qualification & Validation
Comprehensive qualification and validation services that build GMP compliance, sterility assurance and consistent product quality into every system.
Master Validation Plan & the IQ/OQ/PQ Backbone
Every programme runs against a single Master Validation Plan — an integrated framework spanning facility, utilities, equipment and processes — executed through documented Installation, Operational and Performance Qualification.
Installation Qualification
Verifies equipment and systems are installed, connected and calibrated to specification and design intent.
Operational Qualification
Confirms each system operates correctly across its full intended operating range under defined conditions.
Performance Qualification
Demonstrates consistent, reproducible performance under real production conditions — batch after batch.
A Qualified Environment, Qualified Utilities
Facility Validation
- ✓HVAC qualification
- ✓Cleanroom classification (ISO 14644)
- ✓Pressure differentials & room cascades
- ✓Air-change rates & recovery testing
Utility Validation
- ✓Purified Water (PW) generation & loop
- ✓Water for Injection (WFI) loop
- ✓Clean compressed air
- ✓Pure steam & nitrogen systems
Zone-Wise Equipment Validation
Compounding Area
- Mixing tanks, stirrers, balances
- IQ — installation & calibration
- OQ — agitation & weighing accuracy
- PQ — batch homogeneity
Filtration & Sterilization
- Membrane filters
- Autoclaves
- De-pyrogenation tunnels
- SAL ≤ 10⁻⁶ verification
Aseptic Filling
- Filling machines
- Laminar airflow units
- Cappers
- Media-fill validation
Quality Control
- HPLC systems
- Sterility isolators
- LAL systems
- Software validation
Packaging
- Labelers
- Cartoners
- Inspection systems
- Traceability verification
Each zone follows the IQ / OQ / PQ lifecycle with documented protocols, calibration certificates, change-control and preventive-maintenance plans.
Validated Processes, Cleaning & Systems
Equipment & Process
Reproducible production
- ✓IQ / OQ / PQ execution
- ✓Calibration
- ✓Preventive maintenance
- ✓Media fills & batch reproducibility
Cleaning & Analytical
No cross-contamination
- ✓Swab / rinse methods
- ✓Residue limits
- ✓Accuracy & precision
- ✓Method robustness
Computer Systems (CSV)
Data integrity
- ✓Audit trails
- ✓Access control
- ✓Backup verification
- ✓21 CFR Part 11 compliance
Regulatory Alignment & Documentation Control
WHO TRS 986, Annex 2
WHO GMP principles for sterile pharmaceutical products.
EU GMP Annex 15
Qualification & validation requirements under EU GMP.
USFDA 21 CFR Part 211
cGMP for finished pharmaceuticals.
Documentation hierarchy
Validation Master Plan (VMP)
Top-level strategy, scope & responsibilities
Protocols
IQ / OQ / PQ & method protocols
Reports
Executed results & conclusions
Change-Control Records
Controlled change & revalidation
Revalidation & change control
Periodic revalidation, impact assessment and full documentation of modifications.
Best-practice governance
Risk-based validation, a living traceability matrix, and cross-functional review across QA, Engineering & Production.
Why WinHyCare
One accountable partner
Semaglutide API supply plus peptide development and injectable-facility validation — coordinated under one quality system.
Audit-ready by design
Work documented to ICH, WHO, EU GMP and USFDA expectations, so submissions move with fewer questions.
De-risked timelines
Process re-engineering and zero-deficiency dossier support cut regulatory cycles and launch risk.
Scientific depth
Two decades of combined peptide-chemistry and sterile-facility validation experience.
How We Work — One Simple Start
Scope & NDA
Share requirements, sequences or facility plans.
Assess & quote
Technical assessment, timeline and proposal.
Develop / qualify
Process development or qualification design.
Execute & validate
Method, IQ/OQ/PQ and validation execution.
Document & deliver
Dossiers, reports, CoA and Semaglutide supply.
Frequently Asked Questions
Which peptide APIs does WinHyCare supply?
WinHyCare supplies Semaglutide API. The other molecules shown are a reference of therapeutic classes within the scope of our development, analytical and regulatory services — they are listed for reference and are not offered for supply.
What is a CRDMO, and how do you work with partners?
A CRDMO partner provides process development, analytical and regulatory services around an API programme. WinHyCare works as your peptide CRDMO partner — sequence and process optimisation, analytical method development, and DMF/CTD documentation — and supplies Semaglutide API, so peptide programmes are de-risked end to end.
What purity and impurity control should we expect for Semaglutide API?
A target release purity of ≥99.0% by UPLC/HPLC, with individual impurities controlled below 0.10%, confirmed by LC-MS impurity profiling and supported by ICH Q1A(R2) stability data. Each batch ships with a Certificate of Analysis.
Do you support US-DMF and CTD Module 3 filings?
Yes. We support US-DMF Type II dossiers, CTD Module 3 CMC sections, ICH Q2(R1) analytical method-validation packages and stability data, and provide a support desk to help resolve regulator deficiency letters during your filing.
Can you validate our injectable formulation facility?
Yes. We provide qualification and validation services for injectable formulation facilities — a Master Validation Plan, IQ/OQ/PQ execution, facility (HVAC, cleanroom classification) and utility (PW, WFI, gases) validation, aseptic media fills, cleaning validation and computer-system validation (21 CFR Part 11), aligned to WHO TRS 986 Annex 2, EU GMP Annex 15 and USFDA 21 CFR Part 211.
How do you handle global shipping of temperature-sensitive API?
Semaglutide API is shipped through validated cold-chain logistics with active temperature monitoring, thermal packaging and customs documentation for the US, Europe and Asia, with standing supply and safety-stock options to protect your production schedule.
Partner With WinHyCare
Discuss your Semaglutide API requirement, a peptide development programme, or an injectable-facility validation engagement. Explore our peptide reference catalog.